These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 17096299

  • 1. Purine-scaffold Hsp90 inhibitors.
    Chiosis G, Tao H.
    IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
    [Abstract] [Full Text] [Related]

  • 2. Heat shock protein 90: inhibitors in clinical trials.
    Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee WC.
    J Med Chem; 2010 Jan 14; 53(1):3-17. PubMed ID: 20055425
    [No Abstract] [Full Text] [Related]

  • 3. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, Ran Y, Mansfield R, Fritz LC, Ulm E, Burrows FJ, Boehm MF.
    J Med Chem; 2007 Jun 14; 50(12):2767-78. PubMed ID: 17488003
    [Abstract] [Full Text] [Related]

  • 4. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G, Caldas Lopes E, Solit D.
    Curr Opin Investig Drugs; 2006 Jun 14; 7(6):534-41. PubMed ID: 16784024
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
    Llauger L, He H, Kim J, Aguirre J, Rosen N, Peters U, Davies P, Chiosis G.
    J Med Chem; 2005 Apr 21; 48(8):2892-905. PubMed ID: 15828828
    [Abstract] [Full Text] [Related]

  • 6. Assessing the chemical diversity of an hsp90 database.
    Audisio D, Messaoudi S, Ijjaali I, Dubus E, Petitet F, Peyrat JF, Brion JD, Alami M.
    Eur J Med Chem; 2010 May 21; 45(5):2000-9. PubMed ID: 20170986
    [Abstract] [Full Text] [Related]

  • 7. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y, Georges AT, Grenier L, Pak RH, Patterson J, Sydor JR, Tibbitts TT, Tong JK, Adams J, Palombella VJ.
    J Med Chem; 2006 Jul 27; 49(15):4606-15. PubMed ID: 16854066
    [Abstract] [Full Text] [Related]

  • 8. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV, Workman P.
    Endocr Relat Cancer; 2006 Dec 27; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [Abstract] [Full Text] [Related]

  • 9. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y, Ding J.
    Ai Zheng; 2004 Aug 27; 23(8):968-74. PubMed ID: 15301726
    [Abstract] [Full Text] [Related]

  • 10. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).
    Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Sobue G.
    Ann N Y Acad Sci; 2006 Nov 27; 1086():21-34. PubMed ID: 17185503
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Discovery and development of purine-scaffold Hsp90 inhibitors.
    Chiosis G.
    Curr Top Med Chem; 2006 Nov 27; 6(11):1183-91. PubMed ID: 16842155
    [Abstract] [Full Text] [Related]

  • 13. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T, Keum G, Pae AN.
    Expert Opin Ther Pat; 2013 Aug 27; 23(8):919-43. PubMed ID: 23641970
    [Abstract] [Full Text] [Related]

  • 14. Structure-based and in silico design of Hsp90 inhibitors.
    Sgobba M, Rastelli G.
    ChemMedChem; 2009 Sep 27; 4(9):1399-409. PubMed ID: 19685544
    [Abstract] [Full Text] [Related]

  • 15. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.
    Jayanthan A, Fowler J, Hawkins L, Lamers F, Teja B, Incoronato A, Anderson R, Narendran A.
    J Exp Ther Oncol; 2008 Sep 27; 7(3):183-93. PubMed ID: 19066127
    [Abstract] [Full Text] [Related]

  • 16. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T, Ohyashiki K.
    Cancer Lett; 2009 Oct 18; 284(1):62-70. PubMed ID: 19464103
    [Abstract] [Full Text] [Related]

  • 17. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
    Workman P.
    Cancer Lett; 2004 Apr 08; 206(2):149-57. PubMed ID: 15013520
    [Abstract] [Full Text] [Related]

  • 18. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P.
    Cancer Chemother Pharmacol; 2003 Jul 08; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [Abstract] [Full Text] [Related]

  • 19. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
    Zaarur N, Gabai VL, Porco JA, Calderwood S, Sherman MY.
    Cancer Res; 2006 Feb 01; 66(3):1783-91. PubMed ID: 16452239
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.